Best Life Sciences Companies in Planegg, Germany
The 44 best Life Sciences companies in Planegg, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MorphoSys.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Planegg
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MorphoSys Developer of antibodies for treating cancer | $770M | 70 mo ago | 732 | 1992 | Andreas Pluckthun Co-Founder | — | 1,328 patents Therapeutic antibody engineering, formulation, and purification for CD38/CD19 targets | — |
| 2 | Medigene Developer of T cell immunotherapies for haematological malignancies 62Product top 14%Patents top 32%Funding top 34%Innovation top 37% All 12 signals ▾Producttop 14% Patentstop 32% Fundingtop 34% Innovationtop 37% Fin. healthtop 38% Growthtop 40% Moattop 41% Markettop 42% Partnerstop 45% Techbottom 44% Globalbottom 44% Newsbottom 26% Product: 5 distinct product lines · Company stage: Public Patents: 341 patents matched (strict assignee match) · 4 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 27 mo ago | 114 | 1994 | — | WordPressMySQLPHP+18 | 328 patents Liposomal drug delivery systems and immunomodulatory heterocyclic compounds for cancer vaccines | — |
| 3 | SciRhom Developer of drugs for treating autoimmune disease 40Moat top 31%Patents top 32%Funding top 34%Talent top 38% All 8 signals ▾Moattop 31% Patentstop 32% Fundingtop 34% Talenttop 38% Innovationtop 41% Globalbottom 44% Marketbottom 30% Newsbottom 18% Moat: Editorial + unicorn rating 4/10 · IP moat: 29 patents Patents: 29 patents matched (strict assignee match) · 23 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $79M | 25 mo ago | 12 | 2016 | Matthias Schneider Co-Founder & CSO | — | 29 patents Humanized therapeutic antibodies and protein inhibitors targeting iRhom2 for disease treatment | — |
| 4 | Ingenium Pharamceutical Discovering drug targets through Deductive Genomics | $71M | 244 mo ago | 41 | 1999 | John Watkins President & CEO | — | — | — |
| 5 | SuppreMol Developer of therapeutics for the treatment of autoimmune diseases | $71M | 159 mo ago | 50 | 2002 | Jose Almeida CEO | — | 185 patents Therapeutic antibodies and soluble Fc‑receptor formulations for immune modulation | — |
| 6 | U3 Pharma Antibody-based protein therapies primarily for cancer | $49M | 243 mo ago | — | 2001 | Johannes Bange CEO | WordPressMySQLPHP+13 | 214 patents HER3-targeted antibody‑drug conjugates and nucleic‑acid biomarkers for cancer therapy | — |
| 7 | GPC Biotech Developing oncology therapies | $44M | 230 mo ago | — | 1997 | Elmar Maier Co-Founder | — | 126 patents Patents concentrated in health & consumer products | — |
| 8 | 4SC Mid-stage Biotech company discovering & developing small molecule cancer therapies based on epigenetic… | $42M | 125 mo ago | 48 | 1997 | — | WordPressMySQLPHP+10 | 619 patents Small-molecule kinase inhibitors for immuno‑oncology, especially HDAC, DYRK, Kv1.3 targets | — |
| 9 | CPTx Developer of programmable DNA therapeutics for a range of medical challenges 40Growth top 35%Funding top 37%Moat top 38%Talent top 38% All 9 signals ▾Growthtop 35% Fundingtop 37% Moattop 38% Talenttop 38% Techtop 46% Patentstop 50% Innovationbottom 43% Globalbottom 31% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $29.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $29M | 22 mo ago | — | 2021 | Christian Sigl Founder & CTO | WordPressMySQLPHP+19 | 4 patents Formulation and delivery of nucleic‑acid‑based pharmaceuticals | — |
| 10 | Ethris Developer of mRNA therapeutics for infectious diseases 55Patents top 25%Talent top 28%Moat top 29%Product top 30% All 11 signals ▾Patentstop 25% Talenttop 28% Moattop 29% Producttop 30% Innovationtop 35% Fundingtop 36% Growthtop 48% Techbottom 48% Marketbottom 44% Globalbottom 42% Newsbottom 27% Patents: 387 patents matched (strict assignee match) · 116 filings since 2022 vs 192 in 2017-21 Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 15 mo ago | 49 49 → 34 (-31%) | 2009 | — | JimdoApple iCloud MailMicrosoft 365+10 | 387 patents mRNA therapeutic design, purification, and formulation with deuterated nucleotides | — |
| 11 | Dolthera Small molecule therapeutics for inflammatory diseases. | $25M | 215 mo ago | — | — | — | — | — | — |
| 12 | ISAR Bioscience Developer of regenerative medicine | $23M | 33 mo ago | 19 | 2018 | — | Master SliderWordPressMySQL+18 | 15 patents Patents concentrated in chemistry & materials | — |
| 13 | GNA Biosolutions Develops instruments, OEM modules and assays for molecular pathogen detection | $20M | 84 mo ago | 29 | 2010 | — | — | 96 patents Patents concentrated in chemistry & materials | — |
| 14 | AdvanceCOR Developer of drugs and diagnostics for cardiovascular diseases | $11M | 74 mo ago | 16 | 2012 | Gotz Munch Co-Founder & Managing Director | — | 44 patents Cyclic peptide therapeutics targeting autoimmune diseases, especially Graves' disease | — |
| 15 | Dynamic Biosensors Provides solutions for label-free molecular interaction and biophysical analysis | $6M | 47 mo ago | 51 51 → 62 (+22%) | 2011 | — | WordPressMySQLPHP+24 | 33 patents Microfluidic biosensing: high‑flow cell immobilization, bubble control, protein‑small molecule interaction detection. | — |
| 16 | Eisbach Developer of targeted therapy for cancer treatment | $5M | 29 mo ago | 13 | 2019 | Adrian Schomburg Co-Founder & CEO | WordPressMySQLPHP+20 | — | — |
| 17 | Biomax Informatics Knowledge Management Services for the Life Science Industry | $3M | 57 mo ago | 46 | 1997 | — | — | 14 patents AI-driven neuroinformatics and computational pathology for disease detection and analysis | — |
| 18 | Crelux X-ray crystallography, fragment based drug discovery and protein delivery. | $863K | 136 mo ago | 68 | 2005 | Michael Schaeffer Founder & Owner | Animate.cssBootstrapApache HTTP Server+7 | — | — |
| 19 | Ibidi Products and reagents for cell-based assay and microscopy | $817K | 79 mo ago | — | 2001 | Valentin Kahl CEO | PrestaShopMySQLZoho+22 | 147 patents Patents concentrated in transport & manufacturing processes | 1 launch · 1 partnership |
| 20 | Chromo Tek Offering immunologic research tools | $509K | 193 mo ago | 17 | 2008 | — | — | — | — |
| 21 | Sirion Biotech Provides customised AAV based viral vectors and gene therapy | $494K | 127 mo ago | 42 | 2005 | — | — | 79 patents Engineering viral vectors and vaccine platforms for gene therapy and therapeutic vaccines | — |
| 22 | AptaIT Provider of a software tool for data analysis of next-generation sequencing data | $367K | 139 mo ago | — | 2011 | Michael Blank Co-Founder & CSO | — | — | — |
| 23 | Spherotec Developing spheroid microtumor technology for use in drug development and therapy selection | $107K | 111 mo ago | 3 | 2006 | Barbara Mayer Co-Founder & Co-CEO | — | 15 patents Automated production and therapeutic testing of 3D cell spheroids for drug screening | — |
Top 12 Life Sciences companies in Planegg
#1
Series B · Planegg, Bavaria · founded 2009 · 49 employees$26.3Mraised▾
Developer of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics for COVID-19, respiratory diseases, and Primary ciliary dyskinesia (PCD).
- May 2025Grant (prize money)$11.3M
- Jun 2024Series B$5M
- Feb 2022Series B$26.3M
- Jan 2020Grant (prize money)$550.3K
#2
Series B · Planegg, Bavaria · founded 2021$29Mraised▾
Developer of programmable DNA therapeutics for a range of medical challenges. The company leverages its proprietary technology to deliver precision medicine solutions, utilizing a programmable DNA-based approach to target specific diseases such as viruses, cancer, and autoimmune diseases.
- Sep 2024Series B$29M
#3
Series A · Planegg, Bavaria · founded 2016 · 12 employees$79Mraised▾
Developer of drugs for treating autoimmune disease. The product provided inhibits TACE (TNF-alpha converting enzyme or ADAM17) is an essential regulator of signaling pathways, including TNF-alpha and EGFR (epidermal growth factor receptor) signaling. The TACE-dependent release of TNF-alpha and other pro-inflammatory mediators from immune cells is regulated by iRhom2 (RHBDF2, Rhomboid family member 2, refs. 5-7) provided a way to target the pro-inflammatory activities of TACE.
- Jul 2024Series A$70M
- Nov 2021Seed$9M
- Oct 2016Seed—
#4
Public · Planegg, Bavaria · founded 1994 · 114 employees$81.9Mraised▾
Developer of T cell immunotherapies for haematological malignancies. Its product pipeline includes Dendritic cell vaccine for AML and prostate cancer, T cell specific antibodies for leukemia, and T cell receptor based therapy for different cancers.
- May 2024Post IPO$6.4M
- May 2018Post IPO$37.9M
- Jun 2012Post IPO$17.7M
- Mar 2004Post IPO$20M
#5
Acquired · Planegg, Bavaria · founded 1992 · 732 employees$770.1Mraised▾
Developer of antibodies for treating cancer. It is an integrated biopharma company engaged in the discovery, development, and commercialization of therapeutic antibodies for cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction, and inflammation. Their lead candidate is MOR208 for Diffuse large B cell lymphoma (DLBCL). The company's lead technologies include HuCAL (Human Combinatorial Antibody Library), and Ylanthia (the industry’s largest antibody Fab library which uses novel methods for in vitro generation of specific and human antibodies).
- Oct 2020Post IPO$383.8M
- Jan 2020Post IPO$150M
- Nov 2016Post IPO$123.9M
- Sep 2013Post IPO$112.3M
#6
Funding Raised · Planegg, Bavaria · founded 2018 · 19 employees$23.1Mraised▾
ISAR Bioscience is the developer of regenerative medicine. The company uses the induced pluripotent stem cell and genome engineering technologies for developing regenerative medicine. It has collaboration with ldc and Assay.Works to develops therapeutic and discovery technology.
- Nov 2023Grant (prize money)$1M
- Grant (prize money)$22.1M
#7
Series A · Planegg, Bavaria · founded 2019 · 13 employees$4.6Mraised▾
Developer of targeted therapy for cancer treatment. It uses the tumor-suppressor mutant cancer treatment. They have developed the proprietary assay technology that utilizes the modified nucleosomal substrates that help in allosteric regulation of enzyme targets. It also provide genome guide treatment.
- Mar 2024Series A$4.6M
- Nov 2021Grant (prize money)$7.3M
- Jul 2021Grant (prize money)$9.5M
- 2019Seed—
#8
Acquired · Planegg, Bavaria · founded 2011 · 51 employees$5.8Mraised▾
Dynamic Biosensors is a provider of instruments, consumables and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. It has developed a patented switchSENSE technology, a biochip platform for the analysis of molecular interactions. Its products include DRX 2400 analyzer that controls the electrical actuation of biomolecules; Biochip 4x6 which features 24 microelectrodes. It also offers services related to interaction measurements, assay development and data analysis with the samples provided.
- Sep 2022Grant (prize money)$259.1K
- Jan 2019Grant (prize money)$289.7K
- Apr 2018Grant (prize money)$306.9K
- Jan 2018Grant (prize money)$300.8K
#9
Acquired · Planegg, Bavaria · founded 2002 · 50 employees$71Mraised▾
Developer of therapeutics for the treatment of autoimmune diseases. The company's lead candidate is "SM101, a Novel Recombinant, Soluble, Human FcyIIB Receptor, for the Treatment of systemic lupus erythematosus. Also, it develops a pipeline for primary immune thrombocytopenia (ITP), rheumatoid arthritis (RA), and other autoimmune conditions.
- May 2013Series D$20.6M
- Dec 2010Series C$20.2M
- Jul 2008Series B$25M
- May 2006Series A$5.2M
#10
Acquired · Planegg, Bavaria · founded 1999 · 41 employees$71.3Mraised▾
Discovering drug targets through Deductive Genomics. The company has developed complementary biomedical technologies for both drug discovery and drug target validation. Ingenium has developed several drug discovery approaches based on a unique functional analysis of the mammalian genome at the organism level (Deductive Genomics). Its product includes NGENOtyping a novel, high-speed, genetics tool for in vivo validation of gene-based drug targets by providing the most rapid pathway to genetic mouse and rat models. The company is founded as a spin-off from the German Human Genome Project, is a subsidiary of the integrated drug development company Probiodrug.
- Apr 2006Series D$11.1M
- Apr 2005Grant (prize money)$1.4M
- Dec 2003Series C$16.9M
- Sep 2000Series B$43.3M
#11
Public · Planegg, Bavaria · founded 1997 · 48 employees$42.3Mraised▾
4SC AG is a German mid-stage Biotech company discovering & developing small molecule cancer therapies based on epigenetic mechanism of action. It has a "development" division which focuses on clinical development of its own programs and a "Discovery & Collaborative Business", working on early stage research and preclinical work. In Sep 2016, 4SC AG sold its immunology portfolio to Immunic. As of Oct 2016, it has 2 programs in Phase II, and 3 in Phase I studies.
- Mar 2016Grant (prize money)$270.9K
- Jul 2015PE$31.9M
- May 2003Series C$10.4M
#12
Series C · Planegg, Bavaria · founded 2001$49.2Mraised▾
U3 Pharma, a subsidiary of Daiichi Sankyo Company was a clinical-stage biopharmaceutical company focussed on developing the antibody-based next generation targeted therapies for cancer. It has a pipeline of therapeutic antibodies and antibody-drug-conjugates with majority directed against cancer and other selected drugs having the potential to treat cardiovascular or metabolic diseases. Its lead product U3-1287, (Patritumab, AMG888) MAb is directed against the human epidermal growth factor receptor 3 (HER3) a protein that is expressed in many solid tumors has initiated phase 3 studies. Besides, it had 7 pipeline drugs at different development stages for cancer, inflammation and metabolism. In December 2015, it has been closed and has transferred its R&D tasks to the Biologics function of Daiichi Sankyo.
- May 2006Series C$34.5M
- Sep 2003Series B$14.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Germany
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,297 Germany-affiliated papers.
- Heidelberg University85
- German Cancer Research Center49
- Ludwig-Maximilians-Universität München48
- Technical University of Munich43
- Karlsruhe Institute of Technology33
- Gene3→29
- Mutant3→19
- Transcription (linguistics)3→16
- Messenger RNA1→14
- Immune system1→12
- Gene3→20
- Agriculture2→12
- Extracellular1→11
- Immune system1→11
- Transcriptome1→9
- Antibiotic resistance2→9
- Gene1→7
- Agriculture4→9
- Antimicrobial1→4
- Microbiome1→4
Where biotechnology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in Germany
Germany biotechnology patent filing is cooling — 53,233 filings from 8,000 assignees (2016–2025), led by Immatics Biotechnologies, BASF Plant Science, BASF SE; annual filings 4819→4267.
- Immatics Biotechnologies4872
- BASF Plant Science3982
- BASF SE3543
- Boehringer Ingelheim INT3438
- Merck Patent3133
- MAX Planck Gesellschaft1799
- Evonik Degussa1680
- Amgen RES Munich1665
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.